AETC-NMC | Curricula

References

US Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at: http://www.aidsinfo.nih.gov/guidelines. Accessed December 8, 2011.

Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA. 2010;304:321-333.

Severe P, Juste MA, Ambroise A, et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med. 2010;363:257-265.

Blanc FX, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med. 2011;365:1471-1481.

Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009;360:1815-1826.

Kitahata MM. When to start antiretroviral therapy. Top HIV Med. 2010;18:121-126.

When To Start Consortium, Sterne JA, May M, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet. 2009;373:1352-1363.

Ragni MV, Nalesnik MA, Schillo R, Dang Q. Highly active antiretroviral therapy improves ESLD-free survival in HIV-HCV co-infection. Haemophilia. 2009;15:552-558.

El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283-2296.

Uy J, Armon C, Buchacz K, Wood K, Brooks JT. Initiation of HAART at higher CD4 cell counts is associated with a lower frequency of antiretroviral drug resistance mutations at virologic failure. J Acquir Immune Defic Syndr. 2009;51:450-453.

Lichtenstein KA, Armon C, Buchacz K, et al. Initiation of antiretroviral therapy at CD4 cell counts >/=350 cells/mm3 does not increase incidence or risk of peripheral neuropathy, anemia, or renal insufficiency. J Acquir Immune Defic Syndr. 2008;47:27-35.

Marks G, Crepaz N, Janssen RS. Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA. AIDS. 2006;20:1447-1450.

Donnell D, Baeten JM, Kiarie J, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet. 2010;375:2092-2098.

Centers for Disease Control and Prevention. Rapid HIV testing in emergency departments—three US sites, January 2005-March 2006. MMWR Morb Mortal Wkly Rep. 2007;56 :597-601.

Centers for Disease Control and Prevention. Vital signs: HIV testing and diagnosis among adults—United States, 2001-2009. MMWR Morb Mortal Wkly Rep. 2010;59:1550-1555.

Centers for Disease Control and Prevention. Diagnoses of HIV Infection and AIDS in the United States and Dependent Areas, 2009. Atlanta, Georgia. 2011. Available at: http://www.cdc.gov/hiv/surveillance/resources/reports/2009report/index.htm. Accessed December 8, 2011.

Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep. 2009:58(RR-4):1-207.

Brooks JT, Kaplan JE, Holmes KK, Benson C, Pau A, Masur H. HIV-associated opportunistic infections—going, going, but not gone: the continued need for prevention and treatment guidelines. Clin Infect Dis. 2009;48:609-611.

Bartlett JG, Gallant JE, Pham PA. Medical management of HIV infection, 15th edition. Durham, NC: Knowledge Source Solutions; 2009.

Hanson DL, Chu SY, Farizo KM, Ward JW. Distribution of CD4+ T lymphocytes at diagnosis of acquired immunodeficiency syndrome-defining and other human immunodeficiency virus-related illnesses. Arch Intern Med. 1995;155:1537-1542.

Biggar RJ, Chaturvedi AK, Goedert JJ, Engels EA; HIV/AIDS Cancer Match Study. AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst. 2007;99:962-972.

Connick E, Lederman MM, Kotzin BL, et al. Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response. J Infect Dis. 2000;181:358-363.

Landay A, da Silva BA, King MS, et al. Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of lopinavir-ritonavir treatment. Clin Infect Dis. 2007;44:749-754.

Attia S, Egger M, Muller M, et al. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS. 2009;23:1397-1404.

Martinez-Colubi, M. Delayed diagnosis of HIV infection: prevalence risk factors and impact on sanitary costs. Program and abstracts of the 13th European AIDS Conference of the European AIDS Clinical Society (EACS); October 12-15, 2011; Belgrade, Serbia. Abstract PS8/7.

« BACK

	3. Promoting HIV Testing in Diverse Populations Curricula 1 2 3 4 AETC-NMC Home Curricula Home Glossary Feedback

	About Curriculum 3 Module 1: U.S. HIV Epidemiology Learning Objectives & Pretraining Assessment The HIV Epidemic in the United States The HIV Epidemic, cont. By Risk Group Key Events in the US HIV Epidemic (early 1980s - late 1990s) (2000 - present) African American Populations Hispanic/Latino Populations MSM Populations Asian and Pacific Islander Populations American Indian/Native Alaska Populations Summary References Assessment Questions Module 2: Recommendations for Routine HIV Testing Learning Objectives & Pretraining Assessment Development of HIV Screening Recommendations Rationale Underlying the 2006 Recommendations Revised Recommendations for HIV Testing Summary References Assessment Questions Module 3: Benefits of Early Testing and Risks of Delayed Testing Learning Objectives & Pretraining Assessment Timing of Initiation of HAART Guidelines on Starting Antiretroviral Therapy Benefits Associated With Early Therapy Initiation Diagnosis in the ED Risks of Delayed HIV Diagnosis and Treatment Summary References Assessment Questions Module 4: Barriers to Testing and Strategies to Improve Rates of Routine HIV Testing Learning Objectives & Pretraining Assessment Discovering Barriers to Wider Use of HIV Screening Provider-Related Barriers Impact of State and Local Laws and Regulations Population-Specific Barriers Factors That Impede HIV Testing Among Latinos Factors That Impede HIV Testing Among American Indians/Alaska Natives Factors That Impede HIV Testing Among Asian/Pacific Islanders Strategies to Improve Routine HIV Testing Working With Community Organizations Summary References Assessment Questions Module 5: HIV Testing Technologies Learning Objectives & Pretraining Assessment Point-of-Care Testing vs Laboratory-Based Testing Confirmatory Tests Availability of Results Point-of-Care Testing Issues Key Resources for Understanding and Employing HIV Testing Technologies Summary References Assessment Questions Case Studies Suggested Activities	References US Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at: http://www.aidsinfo.nih.gov/guidelines. Accessed December 8, 2011. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA. 2010;304:321-333. Severe P, Juste MA, Ambroise A, et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med. 2010;363:257-265. Blanc FX, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med. 2011;365:1471-1481. Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009;360:1815-1826. Kitahata MM. When to start antiretroviral therapy. Top HIV Med. 2010;18:121-126. When To Start Consortium, Sterne JA, May M, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet. 2009;373:1352-1363. Ragni MV, Nalesnik MA, Schillo R, Dang Q. Highly active antiretroviral therapy improves ESLD-free survival in HIV-HCV co-infection. Haemophilia. 2009;15:552-558. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283-2296. Uy J, Armon C, Buchacz K, Wood K, Brooks JT. Initiation of HAART at higher CD4 cell counts is associated with a lower frequency of antiretroviral drug resistance mutations at virologic failure. J Acquir Immune Defic Syndr. 2009;51:450-453. Lichtenstein KA, Armon C, Buchacz K, et al. Initiation of antiretroviral therapy at CD4 cell counts >/=350 cells/mm3 does not increase incidence or risk of peripheral neuropathy, anemia, or renal insufficiency. J Acquir Immune Defic Syndr. 2008;47:27-35. Marks G, Crepaz N, Janssen RS. Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA. AIDS. 2006;20:1447-1450. Donnell D, Baeten JM, Kiarie J, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet. 2010;375:2092-2098. Centers for Disease Control and Prevention. Rapid HIV testing in emergency departments—three US sites, January 2005-March 2006. MMWR Morb Mortal Wkly Rep. 2007;56 :597-601. Centers for Disease Control and Prevention. Vital signs: HIV testing and diagnosis among adults—United States, 2001-2009. MMWR Morb Mortal Wkly Rep. 2010;59:1550-1555. Centers for Disease Control and Prevention. Diagnoses of HIV Infection and AIDS in the United States and Dependent Areas, 2009. Atlanta, Georgia. 2011. Available at: http://www.cdc.gov/hiv/surveillance/resources/reports/2009report/index.htm. Accessed December 8, 2011. Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep. 2009:58(RR-4):1-207. Brooks JT, Kaplan JE, Holmes KK, Benson C, Pau A, Masur H. HIV-associated opportunistic infections—going, going, but not gone: the continued need for prevention and treatment guidelines. Clin Infect Dis. 2009;48:609-611. Bartlett JG, Gallant JE, Pham PA. Medical management of HIV infection, 15th edition. Durham, NC: Knowledge Source Solutions; 2009. Hanson DL, Chu SY, Farizo KM, Ward JW. Distribution of CD4+ T lymphocytes at diagnosis of acquired immunodeficiency syndrome-defining and other human immunodeficiency virus-related illnesses. Arch Intern Med. 1995;155:1537-1542. Biggar RJ, Chaturvedi AK, Goedert JJ, Engels EA; HIV/AIDS Cancer Match Study. AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst. 2007;99:962-972. Connick E, Lederman MM, Kotzin BL, et al. Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response. J Infect Dis. 2000;181:358-363. Landay A, da Silva BA, King MS, et al. Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of lopinavir-ritonavir treatment. Clin Infect Dis. 2007;44:749-754. Attia S, Egger M, Muller M, et al. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS. 2009;23:1397-1404. Martinez-Colubi, M. Delayed diagnosis of HIV infection: prevalence risk factors and impact on sanitary costs. Program and abstracts of the 13th European AIDS Conference of the European AIDS Clinical Society (EACS); October 12-15, 2011; Belgrade, Serbia. Abstract PS8/7. « BACK NEXT »
	Accessibility · Copyright and Disclaimers © Howard University The AIDS Education and Training Center-National Multicultural Center (AETC-NMC) at Howard University website was made possible by Health Resources and Services Administration, HIV/AIDS Bureau (HAB) of the U.S. Department of Health and Human Services (grant #U2THA19645).

3. Promoting HIV Testing in Diverse Populations

References